However, Vav/NPM-ALK transgenic mice mainly developed plasmacytomas, suggesting that perhaps NPM-ALK is more potent when expressed in B cells or that, as expected and observed, B cells are more prone to transformation than T cells (B-cell lymphoma is far more prominent than T-cell lymphoma in humans). The gene discussed is ALK; the disease is T-cell non-Hodgkin lymphoma.